Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
Aneurysm I: Introduction01:30

Aneurysm I: Introduction

An aortic aneurysm is a localized outpouching or dilation at a weak point in the artery wall. It may involve different parts of the aorta, such as the abdominal aorta, aortic arch, or thoracic aorta.Etiological factorsSeveral disorders are associated with aortic aneurysms.Congenital causes, such as primary connective tissue disorders like Marfan syndrome, impact the integrity and strength of connective tissues, notably affecting the aorta. Marfan syndrome is a genetic disorder that specifically...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Reported Case of Hemoglobin Graz in the United States: Implications for Misleading Hemoglobin A<sub>1c</sub> Results.

JCEM case reports·2024
Same author

Smartphone-based machine learning model for real-time assessment of medical kidney biopsy.

Journal of pathology informatics·2024
Same author

Prevalence of Phenotypic Hypertrophic Cardiomyopathy Among Student Sports Participants.

The American journal of cardiology·2024
Same author

Metformin toxicity in the intensive care unit: A case series and review of the literature.

International journal of critical illness and injury science·2024
Same author

Fatal hemorrhagic bronchopneumonia caused by <i>Bordetella bronchiseptica</i> in an immunocompetent patient.

Germs·2023
Same author

Extrinsic lipoid pneumonia due to chronic polyethylene glycol consumption: A case report.

Respiratory investigation·2023

Related Experiment Video

Updated: Jun 22, 2026

A Mouse Abdominal Aortic Aneurysm Model by Periadventitial Calcium Chloride and Elastase Infiltration
05:07

A Mouse Abdominal Aortic Aneurysm Model by Periadventitial Calcium Chloride and Elastase Infiltration

Published on: August 2, 2024

Molecular targets and abdominal aortic aneurysms.

Sudip Nanda1, Shree G Sharma, Santo Longo

  • 1Department of Internal Medicine, St. Luke's Hospital, 801 Ostrum Street, Bethlehem, PA 18015, USA. sudipnanda2000@yahoo.com

Recent Patents on Cardiovascular Drug Discovery
|June 13, 2009
PubMed
Summary

New medications could prevent or slow the progression of abdominal aortic aneurysm (AAA) by 50%, potentially reducing the need for surgery in older patients. Research focuses on inhibiting key molecular pathways involved in AAA development.

More Related Videos

Ultrasound Imaging of the Thoracic and Abdominal Aorta in Mice to Determine Aneurysm Dimensions
06:08

Ultrasound Imaging of the Thoracic and Abdominal Aorta in Mice to Determine Aneurysm Dimensions

Published on: March 8, 2019

Advanced Abdominal Aortic Aneurysm Modeling in Mice by Combination of Topical Elastase and Oral &#223;-aminopropionitrile
07:42

Advanced Abdominal Aortic Aneurysm Modeling in Mice by Combination of Topical Elastase and Oral ß-aminopropionitrile

Published on: July 26, 2024

Related Experiment Videos

Last Updated: Jun 22, 2026

A Mouse Abdominal Aortic Aneurysm Model by Periadventitial Calcium Chloride and Elastase Infiltration
05:07

A Mouse Abdominal Aortic Aneurysm Model by Periadventitial Calcium Chloride and Elastase Infiltration

Published on: August 2, 2024

Ultrasound Imaging of the Thoracic and Abdominal Aorta in Mice to Determine Aneurysm Dimensions
06:08

Ultrasound Imaging of the Thoracic and Abdominal Aorta in Mice to Determine Aneurysm Dimensions

Published on: March 8, 2019

Advanced Abdominal Aortic Aneurysm Modeling in Mice by Combination of Topical Elastase and Oral &#223;-aminopropionitrile
07:42

Advanced Abdominal Aortic Aneurysm Modeling in Mice by Combination of Topical Elastase and Oral ß-aminopropionitrile

Published on: July 26, 2024

Area of Science:

  • Vascular Biology
  • Medical Chemistry
  • Cardiovascular Research

Background:

  • Abdominal aortic aneurysm (AAA) presents a significant health challenge in the United States.
  • Current treatments, surgery and endovascular stenting, are invasive, and effective medical therapies for regression are lacking.
  • Preventing or slowing AAA progression could avert unnecessary interventions for many older individuals.

Purpose of the Study:

  • To review the molecular pathogenesis of AAA.
  • To discuss newly developed therapeutic agents targeting these pathways.
  • To explore the potential of novel medications in preventing AAA expansion.

Main Methods:

  • Review of basic research on AAA molecular pathogenesis.
  • Identification of key mediators involved in aortic damage.
  • Discussion of newly patented agents and their mechanisms of action.

Main Results:

  • AAA pathogenesis involves multiple mediators like angiotensin II, interleukins, and various kinases.
  • These mediators activate proteases, leading to aortic wall degradation and smooth muscle cell apoptosis.
  • New molecules targeting these pathways are under development to inhibit AAA progression.

Conclusions:

  • Understanding AAA molecular pathways has spurred the development of novel therapeutic agents.
  • These agents aim to inhibit key pathogenetic mechanisms and delay AAA expansion.
  • Patented agents show promise in preventing the progression of abdominal aortic aneurysms.